HPC The Hydration Pharmaceuticals Company Limited
Consumer Defensive · Food Distribution
· website
$0.00
52wk 0.00 – 0.02
Overall
28.8
Value
90.8
Growth
0.0
Health
39.0
Quality
0.0
Momentum
0.0
Dividend
—
Price
About The Hydration Pharmaceuticals Company Limited
The Hydration Pharmaceuticals Company Limited, together with its subsidiaries, markets and sells a range of liquid, tablet, and powder healthy hydration products in Australia, Canada, and the United States. It sells its products under the Hydralyte brand through retail stores and online. The company was founded in 2001 and is based in Melbourne, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 0.0% |
| 1 month | 0.0% |
| 3 months | -25.0% |
| 6 months | -25.0% |
| 1 year | -75.0% |
| 3 years | -91.9% |
Risk
| Volatility (1y ann.) | 126.4% |
| Beta vs ASX 200 | 0.19 |
| Sharpe (1y) | -0.50 |
| VaR 95% (1-day) | -16.7% |
| Max drawdown (1y) | -70.0% |
| Off 1-year high | -70.0% |
Technicals
| RSI(14) | 100 OB |
| vs 50DMA | -16.7% |
| vs 200DMA | -27.7% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
90.8
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
—
Price / Book
82
Price / Sales
100
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
0
EPS growth (1y)
0
EPS CAGR (3y)
—
Financial Health
39.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
78
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
0.0
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
0
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$1.61M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.95
EV / EBITDA
—
Price / Book
2.13
ROE
-147.4%
Operating margin
-102.3%
Net margin
-115.4%
Total cash
$442,919
Total debt
$0
Current ratio
2.13
Debt / Equity
—
Free cash flow
$-1.28M
Avg volume
197,218
Latest annual results
(FY ending 31 Dec 2025)
- Revenue$2.47M
- Gross profit$1.36M
- Operating income-$3.15M
- Net income-$2.86M
- Diluted EPS-0.01
- Free cash flow-$3.65M
- Net debt-$1.12M